Biologics API market seen topping $106 billion by 2030

The biologics active pharmaceutical ingredient market is projected to surpass $106 billion by 2030, driven by demand for monoclonal antibodies, biosimilars and advanced biologic therapies. North America is expected to lead the market, with the United States the biggest country market and monoclonal antibodies the largest product segment.

Why it matters: - The biologics API market is becoming a bigger piece of pharmaceutical manufacturing as demand rises for biologic therapies, biosimilars and complex treatments for cancer, autoimmune disease and rare disorders. - The market is forecast to exceed $106.19 billion by 2030, or about 4% of the projected $2.496 trillion global pharmaceuticals market. - Growth in biologics APIs affects drug supply chains, manufacturing investment and access to high-value therapies worldwide.

What happened: - The Business Research Company released its The Biologics Active Pharmaceutical Ingredient (API) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the biologics API market will grow at a 10% compound annual growth rate through 2030. - North America is forecast to reach $41 billion by 2030, up from $26 billion in 2025. - The United States is projected to be the largest single-country market at $37 billion in 2030, up from $23 billion in 2025. - Monoclonal antibodies are expected to be the largest modality segment, at 49% of the market and about $52 billion in 2030. - The report identifies Lonza Group AG as the 2025 global sales leader with a 4% market share.

The details: - North America’s growth is tied to rising production of monoclonal antibodies and recombinant proteins, plus demand for biologic therapies and biosimilars, expanded biopharmaceutical capacity, cell and gene therapy research, single-use bioprocessing and the presence of specialized biologics manufacturers and CDMOs. - U.S. growth is supported by more approvals for biologic drugs and complex therapies, higher demand for therapeutic proteins, expansion of advanced biomanufacturing sites, continuous bioprocessing, sophisticated purification technologies, outsourcing and collaboration between pharma and biotech companies. - The report says biosimilar development will add roughly 1.4% annual growth, as patent expirations open the door to lower-cost alternatives. - Increased biopharmaceutical R&D is expected to add about 2.3% annual growth, driven by funding from private investors, industry and public health agencies. - The market is organized by scale of operation, service line and end user, including preclinical or clinical and commercial production; upstream processing, downstream purification, fill-finish and analytical testing; and customers such as pharmaceutical companies, biotech firms, academic institutions and contract research organizations. - The monoclonal antibodies, recombinant proteins, vaccines, enzymes and other biologics segments are projected to contribute more than $39 billion in market value by 2030. - Over the next five years, monoclonal antibodies are expected to add $21 billion, recombinant proteins $8 billion, vaccines $6 billion, enzymes $2 billion and other biologics $2 billion. - The report also lists major companies active in the market, including Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific, Fujifilm Biotechnologies, Roche, Boehringer Ingelheim, Amgen, AbbVie, Sanofi, Eli Lilly, AstraZeneca, Novartis, Pfizer and GSK.

Between the lines: - The market remains relatively fragmented, with the top 10 companies accounting for just 12% of revenue in 2025. - High regulatory barriers, capital intensity and technical complexity are helping keep the field fragmented while favoring companies with large-scale manufacturing and CDMO capabilities. - Expansion activity points to a push toward more capacity for complex biologics, including antibody-drug conjugates and other advanced modalities. - Veranova expanded its Devens, Massachusetts facility in June 2025 with added bioconjugation development and production capacity, while Enzene Biosciences expanded its biologics manufacturing site in Hopewell, New Jersey. - The report says companies are leaning on bioprocessing advances, cell culture technologies, recombinant DNA and bioconjugation platforms, plus automation and AI analytics, to improve yield, purity and process control.

What's next: - The report expects continued demand growth as biologic therapies, biosimilars and next-generation biologics move deeper into commercial pipelines. - Capacity expansions, outsourcing and process innovation are likely to remain central as manufacturers try to meet demand for monoclonal antibodies, recombinant proteins and other complex biologics. - The most competitive companies will likely be those that can scale manufacturing, maintain quality standards and adapt to continuous and single-use processing models.

The bottom line: - Biologics APIs are moving from a niche category to a major growth engine in pharma manufacturing, with monoclonal antibodies leading the way and North America still setting the pace.